ZY - Zymergen expands agreement with Octant on developing breakthrough medicines
- Biotech company Zymergen ( NASDAQ: ZY ) expanded an agreement with therapeutics company Octant in relation to developing breakthrough medicines.
- Octant has more than doubled its initial investment through the purchase of six additional Reconfigurable Automation Carts, or RAC, units.
- ZY shares were trading +2.15% post-market.
- Source: Press Release
For further details see:
Zymergen expands agreement with Octant on developing breakthrough medicines